UY38049A - Anti-pd-1 anticuerpos y métodos de tratamiento - Google Patents

Anti-pd-1 anticuerpos y métodos de tratamiento

Info

Publication number
UY38049A
UY38049A UY0001038049A UY38049A UY38049A UY 38049 A UY38049 A UY 38049A UY 0001038049 A UY0001038049 A UY 0001038049A UY 38049 A UY38049 A UY 38049A UY 38049 A UY38049 A UY 38049A
Authority
UY
Uruguay
Prior art keywords
antibodies
treatment methods
methods
antigen binding
binding proteins
Prior art date
Application number
UY0001038049A
Other languages
English (en)
Inventor
M K Z Ali Khaled
Jagdish Agrawal Neeraj
Ian Foltz
Darren Bates
Marissa Mock
Shunsuke Takenaka
Gunasekaran Kannan
Zhulun Wang
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of UY38049A publication Critical patent/UY38049A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se proporcionan proteínas de unión al antígeno PD-1 y ácidos nucleicos, vectores, células hospedadoras, kits y composiciones farmacéuticas relacionadas. También se proporcionan métodos para elaborar proteínas de unión al antígeno PD-1 y métodos para tratar a un sujeto.
UY0001038049A 2018-01-12 2019-01-11 Anti-pd-1 anticuerpos y métodos de tratamiento UY38049A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862616733P 2018-01-12 2018-01-12
US201862770029P 2018-11-20 2018-11-20

Publications (1)

Publication Number Publication Date
UY38049A true UY38049A (es) 2019-07-31

Family

ID=65279666

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038049A UY38049A (es) 2018-01-12 2019-01-11 Anti-pd-1 anticuerpos y métodos de tratamiento

Country Status (24)

Country Link
US (1) US11518808B2 (es)
EP (1) EP3737694B1 (es)
JP (1) JP2019122373A (es)
KR (1) KR20200110358A (es)
CN (1) CN111727197A (es)
AU (1) AU2019207895A1 (es)
BR (1) BR112020014121A2 (es)
CA (1) CA3087273A1 (es)
CL (1) CL2020001820A1 (es)
CO (1) CO2020009234A2 (es)
CR (2) CR20200330A (es)
ES (1) ES2941740T3 (es)
IL (1) IL275096A (es)
JO (1) JOP20200172A1 (es)
MA (1) MA51631A (es)
MX (1) MX2020007291A (es)
PE (1) PE20211270A1 (es)
PH (1) PH12020550967A1 (es)
SG (1) SG11202005605SA (es)
TN (1) TN2020000142A1 (es)
TW (1) TW201930344A (es)
UY (1) UY38049A (es)
WO (1) WO2019140196A1 (es)
ZA (1) ZA202004735B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017201019A1 (en) 2016-05-17 2017-11-23 Chimera Bioengineering, Inc. Methods for making novel antigen binding domains
WO2018045177A1 (en) 2016-09-01 2018-03-08 Chimera Bioengineering, Inc. Gold optimized car t-cells
CN106834228B (zh) * 2017-01-17 2021-03-23 上海新长安生物科技有限公司 一种体外扩增cd8+t细胞及其细胞亚群的方法
US11110125B2 (en) 2018-02-13 2021-09-07 Chimera Bioengineering, Inc. Coordinating gene expression using RNA destabilizing elements
EP3829633A1 (en) 2018-08-03 2021-06-09 Amgen Research (Munich) GmbH Antibody constructs for cldn18.2 and cd3
AU2020303986A1 (en) 2019-06-24 2021-12-09 Amgen Inc. Inhibition of SIRP-gamma for cancer treatment
WO2021034653A1 (en) 2019-08-18 2021-02-25 Chimera Bioengineering, Inc. Combination therapy with gold controlled transgenes
CN114599681B (zh) * 2019-10-25 2024-01-09 上海药明生物技术有限公司 新型抗cd47抗体及其用途
WO2021092355A1 (en) * 2019-11-08 2021-05-14 Amgen Inc. Engineering charge pair mutations for pairing of hetero-igg molecules
JP2023504884A (ja) * 2019-12-05 2023-02-07 ヴィセリックス・インコーポレーティッド ユニバーサル細胞療法のための免疫逃避機構のモジュレーター
JP7392145B2 (ja) * 2019-12-20 2023-12-05 山東博安生物技術股▲ふん▼有限公司 免疫療法のためのｔ細胞二重特異性抗体の作製における最適化された抗ｃｄ３アーム
WO2021121373A1 (zh) * 2019-12-20 2021-06-24 广东菲鹏制药股份有限公司 抗人程序死亡因子-1单克隆抗体
CN116096751A (zh) * 2020-02-25 2023-05-09 璟尚生物制药公司 三特异性t细胞接合器
US20230273126A1 (en) 2020-06-04 2023-08-31 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
CA3187576A1 (en) 2020-06-26 2021-12-30 Amgen Inc. Il-10 muteins and fusion proteins thereof
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
WO2022060878A1 (en) 2020-09-16 2022-03-24 Amgen Inc. Methods for treating prostate cancer
CN112516319A (zh) * 2020-12-08 2021-03-19 华中农业大学 用于治疗乳腺癌的组合药剂
CA3213789A1 (en) * 2021-04-02 2022-10-06 Krystal Biotech, Inc. Viral vectors for cancer therapy
CA3217850A1 (en) 2021-04-27 2022-11-03 Amgen Inc. Modulating product quality of asymmetric multispecific antibodies through the use of temperature
WO2022240722A1 (en) 2021-05-10 2022-11-17 Amgen Inc. Anti-pd-1 antibody dosing for cancer treatment
CA3219181A1 (en) * 2021-05-19 2022-11-24 Yik Andy Yeung Il-21 polypeptides and targeted constructs
IL308808A (en) 2021-06-04 2024-01-01 Amgen Inc Antibodies against CCR8 and their uses
CA3221250A1 (en) 2021-06-04 2022-12-08 Amgen Research (Munich) Gmbh T cell engager molecules and uses thereof
TW202319398A (zh) 2021-08-12 2023-05-16 美商安進公司 抗體配製物
WO2023137161A1 (en) 2022-01-14 2023-07-20 Amgen Inc. Triple blockade of tigit, cd112r, and pd-l1

Family Cites Families (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0623679B1 (en) 1987-05-21 2003-06-25 Micromet AG Targeted multifunctional proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6770274B1 (en) 1990-09-14 2004-08-03 The General Hospital Corporation Viral mutant HSV mediated destruction of neoplastic cells
US5780279A (en) 1990-12-03 1998-07-14 Genentech, Inc. Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
JP3266311B2 (ja) 1991-05-02 2002-03-18 生化学工業株式会社 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Tech Verfahren zur herstellung von spezifischen bindungspaargliedern
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US5855885A (en) 1993-01-22 1999-01-05 Smith; Rodger Isolation and production of catalytic antibodies using phage technology
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
US6699468B1 (en) 1994-06-23 2004-03-02 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5702892A (en) 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5824318A (en) 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
KR20080059467A (ko) 1996-12-03 2008-06-27 아브게닉스, 인크. 복수의 ｖｈ 및 ｖｋ 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
US6379674B1 (en) 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
AU2546399A (en) 1998-02-10 1999-08-30 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
BRPI9909860B8 (pt) 1998-04-21 2021-05-25 Amgen Res Munich Gmbh polipeptídeo multifuncional de cadeia simples, polinucleotídeo, vetor, célula procariótica, de levedura ou unicelular, composição, usos de polipeptídeo e polinucleotídeo e métodos para preparo do referido polipeptídeo e para identificação de ativadores ou inibidores de ativação ou estimulação das células t
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
WO2000040734A1 (en) 1998-12-31 2000-07-13 Arch Development Corporation Recombinant herpes simplex virus useful for treating neoplastic disease
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
WO2000054795A1 (en) 1999-03-15 2000-09-21 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6764675B1 (en) 1999-06-08 2004-07-20 The Uab Research Foundation Herpes simplex virus expressing foreign genes and method for treating cancers therewith
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
KR100768408B1 (ko) 2000-01-21 2007-10-18 바이오벡스 리미티드 헤르페스 바이러스 주
US20020197266A1 (en) 2000-02-08 2002-12-26 Waldemar Debinski Immunotherapy using interleukin 13 receptor subunit alpha 2
JP4212897B2 (ja) 2001-03-27 2009-01-21 具紀 藤堂 ウイルスおよび治療法におけるそれらの使用
AR036993A1 (es) * 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
AU2002336676A1 (en) 2001-11-05 2003-05-19 Zymogenetics, Inc Il-21 antagonists
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
EP2840089A1 (en) 2002-01-18 2015-02-25 ZymoGenetics, Inc. Cytokine receptor zcytor17 multimers
US7736652B2 (en) 2002-03-21 2010-06-15 The Regents Of The University Of California Antibody fusion proteins: effective adjuvants of protein vaccination
JP2006514601A (ja) 2002-06-07 2006-05-11 ザイモジェネティクス インコーポレイティッド ガンおよびその他の治療用途におけるｉｌ−２１の使用方法
EP1551505B1 (en) 2002-10-04 2010-02-24 Microchips, Inc. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
CN1513993A (zh) 2002-12-31 2004-07-21 北京博泰迪生物工程科技开发有限公司 中国人基因组cDNA文库白细胞介素21的编码基因序列及其蛋白质的氨基酸序列
CA2522586C (en) 2003-05-31 2017-02-21 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
AU2004275871A1 (en) 2003-09-25 2005-04-07 Zymogenetics, Inc. Methods of treating autoimmune diseases using IL-21
BRPI0415457A (pt) 2003-10-16 2006-12-05 Micromet Ag constructo de ligação especìfico de cd3 citotoxicamente ativo, seu processo de produção, composição compreendendo o mesmo, seqüência de ácido nucléico, vetor, hospedeiro, seus usos na preparação de uma composição farmacêutica e kit compreendendo os mesmo
SG10201606980VA (en) 2004-06-03 2016-10-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
US7731952B2 (en) 2004-06-24 2010-06-08 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
ATE537170T1 (de) 2005-03-14 2011-12-15 Merck Sharp & Dohme Cgrp-rezeptorantagonisten
BRPI0609079A2 (pt) 2005-04-18 2010-11-16 Novo Nordisk As peptìdeo, composição farmacêutica, método para o tratamento de cáncer, uso de um peptìdeo construto de ácido nucleico, vetor, hospedeiro, e, anticorpo
ES2427646T5 (es) * 2005-05-09 2017-08-22 Ono Pharmaceutical Co., Ltd. Anticuerpos monoclonales humanos contra muerte programada 1 (PD1) y métodos para el tratamiento del cáncer mediante el uso de anticuerpos anti-PD-1 solos o combinados con otros agentes inmunoterapéuticos
JP5322653B2 (ja) 2005-11-28 2013-10-23 ザイモジェネティクス， インコーポレイテッド Ｉｌ−２１アンタゴニスト
US7592427B2 (en) 2005-11-28 2009-09-22 Zymogenetics, Inc. Antibodies to IL-21 receptor
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
WO2007128563A1 (en) 2006-05-08 2007-11-15 Philogen Spa Antibody-targeted cytokines for therapy
EP2091968A2 (en) 2006-10-26 2009-08-26 Novo Nordisk A/S Il-21 variants
CA2671665A1 (en) 2006-12-21 2008-06-26 Novo-Nordisk A/S Interleukin-21 variants with altered binding to the il-21 receptor
CN101230335B (zh) 2007-01-22 2010-08-11 北京奥源和力生物技术有限公司 单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物
CN101230334B (zh) 2007-01-22 2011-06-01 北京奥源和力生物技术有限公司 单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物
AU2008234020B2 (en) 2007-04-03 2013-02-07 Amgen Research (Munich) Gmbh Cross-species-specific CD3-epsilon binding domain
PL2155783T5 (pl) 2007-04-03 2023-03-13 Amgen Research (Munich) Gmbh Swoista międzygatunkowo domena wiążąca CD3epsilon
CN101657190B (zh) 2007-04-19 2013-09-11 东亚制药株式会社 一种适用于对葡萄糖控制肽进行控释的可生物降解的微球组合物及其制剂
CN102027011B (zh) 2007-12-07 2014-09-03 津莫吉尼蒂克斯公司 抗人il-21单克隆抗体
EP2262837A4 (en) * 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
JP2011516603A (ja) 2008-04-17 2011-05-26 アブリンクス エン．ヴェー． 血清タンパク質と結合することが可能なペプチド、並びにこれを含む化合物、構築物及びポリペプチド
EP2328919A2 (en) * 2008-08-25 2011-06-08 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
PT2356153T (pt) 2008-10-01 2016-07-15 Amgen Res (Munich) Gmbh Anticorpo biespecífico, de cadeia única, amepxcd3, específico interespécies
US20120107267A1 (en) * 2009-03-11 2012-05-03 Novo Nordisk A/S Interleukin-21 variants having antagonistic binding to the il-21 receptor
JP5501439B2 (ja) 2009-04-02 2014-05-21 ロシュ グリクアート アクチェンゲゼルシャフト 完全長抗体と単鎖Ｆａｂフラグメントとを含む多重特異的抗体
RU2522002C2 (ru) 2009-06-26 2014-07-10 Ридженерон Фармасьютикалз, Инк. Легковыделяемые биспецифические антитела с природным иммуноглобулиновым форматом
SG178443A1 (en) 2009-08-17 2012-04-27 Roche Glycart Ag Targeted immunoconjugates
JP2013509170A (ja) 2009-10-30 2013-03-14 ノボザイムス バイオファーマ デーコー アクティーゼルスカブ アルブミン変異体
IL300733A (en) 2010-03-05 2023-04-01 Univ Johns Hopkins Compositions and methods for antibodies and fusion proteins targeting immune modulation
US20130225496A1 (en) 2010-11-01 2013-08-29 Novozymes Biopharma Dk A/S Albumin Variants
JP2014511147A (ja) 2011-02-10 2014-05-12 ロシュ グリクアート アーゲー 改善された免疫療法
CA2829628A1 (en) 2011-03-11 2012-09-20 Amgen Inc. Method of correlated mutational analysis to improve therapeutic antibodies
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
RU2650784C2 (ru) 2011-05-05 2018-04-17 Альбумедикс А/С Варианты альбумина
WO2012178137A1 (en) 2011-06-24 2012-12-27 Gillies Stephen D Light chain immunoglobulin fusion proteins and methods of use thereof
US20130028882A1 (en) 2011-07-07 2013-01-31 Humanitas Technology, LLC Antiviral compositions and methods of their use
RS58146B1 (sr) 2011-09-08 2019-02-28 Univ New York Onkolitički herpes simpleks virus i njegova terapeutska upotreba
EP3559049A4 (en) 2011-10-28 2019-12-04 Teva Pharmaceuticals Australia Pty Ltd POLYPEPTIDE CONSTRUCTS AND APPLICATIONS THEREOF
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
US20150030562A1 (en) 2011-12-23 2015-01-29 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Methods of treating or preventing viral diseases by blocking interleukin-21
WO2013109904A1 (en) 2012-01-19 2013-07-25 University Of Miami Compositions, methods and kits for treatment of cancer and autoimmune diseases
KR20140136934A (ko) 2012-03-16 2014-12-01 노보자임스 바이오파마 디케이 에이/에스 알부민 변이체
MY174248A (en) 2012-04-30 2020-04-01 Biocon Ltd Targeted/immunomodulatory fusion proteins and methods for making same
EP2847219A1 (en) * 2012-05-07 2015-03-18 Amgen Inc. Anti-erythropoietin antibodies
WO2013169693A1 (en) 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
MX365382B (es) 2012-08-07 2019-05-31 Roche Glycart Ag Una combinación de inmunoconjugado y anticuerpo para usarse en el tratamiento de cáncer.
BR112015010318A2 (pt) 2012-11-08 2017-08-22 Albumedix As Variantes de albumina
CN105518143B (zh) 2013-03-15 2020-02-21 北京凯得尔森生物技术有限公司 融合蛋白分子和它的使用方法
CN105339389B (zh) 2013-05-02 2021-04-27 安奈普泰斯生物有限公司 针对程序性死亡-1(pd-1)的抗体
WO2015000585A1 (en) * 2013-07-02 2015-01-08 Walter Sebald Muteins of cytokines of the gamma-chain receptor family conjugated to a non-protein group
US10683353B2 (en) 2013-07-11 2020-06-16 The Scripps Research Institute Coiled coil immunoglobulin fusion proteins and compositions thereof
CN105026428B (zh) 2013-12-12 2018-01-16 上海恒瑞医药有限公司 PD‑l抗体、其抗原结合片段及其医药用途
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
MX2016010174A (es) 2014-02-06 2016-11-15 Hoffmann La Roche Proteinas de fusion de interleucina-10 y usos de las mismas.
KR20160120335A (ko) 2014-02-19 2016-10-17 메르크 파텐트 게엠베하 암-표적화된 ｉｌ-12 면역요법
CA3208721A1 (en) 2014-04-08 2015-10-15 Boston Pharmaceuticals Inc. Binding molecules specific for il-21 and uses thereof
CN104403004B (zh) 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
EP3233192B1 (en) 2014-12-15 2021-04-14 Washington University Compositions and methods for targeted cytokine delivery
US10940212B2 (en) 2014-12-19 2021-03-09 Monash University IL-21 agonist antibodies and methods of treatment using same
WO2016096858A1 (en) 2014-12-19 2016-06-23 Mabtech Ab Composition, kit and method for inhibition of il-21 mediated activation of human cells
KR20160113452A (ko) 2015-03-20 2016-09-29 (주)엘지하우시스 진공 단열재용 심재 및 진공단열재
DK3328419T3 (da) 2015-07-30 2021-10-11 Macrogenics Inc Pd-1-bindingsmolekyler og fremgangsmåder til anvendelse deraf
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TW202346349A (zh) 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Dll3及cd3抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
CA2993429A1 (en) 2015-07-31 2017-02-09 Tarveda Therapeutics, Inc. Compositions and methods for immuno-oncology therapies
JP6883579B2 (ja) 2015-08-11 2021-06-09 ウーシー バイオロジクス（ケイマン）インコーポレイテッド 新規抗ｐｄ−１抗体
EA201890630A1 (ru) 2015-09-01 2018-10-31 Эйдженус Инк. Антитела против pd-1 и способы их применения
PE20181092A1 (es) 2015-10-02 2018-07-09 Hoffmann La Roche Anticuerpos anti-pd1 y metodos de uso
PL3370768T3 (pl) 2015-11-03 2022-06-13 Janssen Biotech, Inc. Przeciwciała specyficznie wiążące pd-1 i ich zastosowania
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
HUE063377T2 (hu) * 2015-12-22 2024-01-28 Regeneron Pharma Anti-PD-1 antitestek és bispecifikus anti-CD20/anti-CD3 antitestek kombinációja a rák kezelésére
EP4219696A3 (en) 2016-01-08 2023-09-27 Replimune Limited Oncolytic virus strain
WO2017123643A1 (en) 2016-01-11 2017-07-20 Flagship Pioneering, Inc. Methods and compositions for modulating thymic function
UA126656C2 (uk) 2016-02-03 2023-01-11 Емджен Рісерч (Мюнік) Гмбх Біспецифічна конструкція антитіла до psma і cd3, яке залучають t-клітини
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
MA43955B1 (fr) 2016-02-03 2022-02-28 Amgen Inc Anticorps anti-bcma et anti-cd3 bispécifiques de format bite
WO2017136818A2 (en) 2016-02-05 2017-08-10 Washington University Compositions and methods for targeted cytokine delivery
EP3411397A1 (en) 2016-02-05 2018-12-12 Orionis Biosciences NV Cd8 binding agents
WO2017158436A1 (en) 2016-03-17 2017-09-21 Oslo Universitetssykehus Hf Fusion proteins targeting tumour associated macrophages for treating cancer
EP3433281A1 (en) 2016-03-21 2019-01-30 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
CR20180518A (es) 2016-04-01 2019-04-25 Kite Pharma Inc Receptores quiméricos de flt3 y métodos de uso de los mismos
IL262385B2 (en) 2016-04-22 2024-01-01 Immvira Co Ltd Structure of a recombinant herpes simplex virus-committed vector and constructs for cancer therapy
BR112019000015A2 (pt) 2016-06-30 2019-04-24 Oncorus, Inc. distribuição por vírus oncolítico pseudotipado de polipeptídeos terapêuticos
RU2656181C1 (ru) 2016-07-13 2018-05-31 Закрытое Акционерное Общество "Биокад" Анти-pd-1-антитела, способ их получения и способ применения
EP3490583B1 (en) 2016-08-01 2023-11-29 Virogin Biotech Canada Ltd Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules
KR101928981B1 (ko) 2016-09-02 2018-12-13 고려대학교 산학협력단 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물
TN2019000081A1 (en) 2016-09-14 2020-07-15 Beijing hanmi pharm co ltd Antibody specifically binding to pd-1 and functional fragment thereof
AU2016423559C1 (en) 2016-09-21 2020-11-19 Cstone Pharmaceuticals The novel monoclonal antibodies to programmed death 1 (PD-1)
US20190209652A1 (en) 2016-09-23 2019-07-11 Oncosec Medical Incorporated Modulating responses to checkpoint inhibitor therapy
CA3039992A1 (en) 2016-11-02 2018-05-11 Jounce Therapeutics, Inc. Antibodies to pd-1 and uses thereof
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
CN107082812B (zh) 2017-03-29 2018-11-13 上海科医联创生物科技有限公司 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
AU2018247765B2 (en) 2017-04-03 2023-11-23 F. Hoffmann-La Roche Ag Immunoconjugates of an Anti-PD-1 antibody with a mutant IL-2 or with IL-15
KR20200037781A (ko) 2017-07-03 2020-04-09 토크 테라퓨틱스, 인코포레이티드 면역자극 융합 분자 및 이의 용도
JP2021515599A (ja) 2018-03-09 2021-06-24 アスクジーン・ファーマ・インコーポレイテッドＡｓｋＧｅｎｅ Ｐｈａｒｍａ， Ｉｎｃ． 新規のサイトカインプロドラッグ
JP2021519089A (ja) 2018-03-28 2021-08-10 オリオニス バイオサイエンシーズ，インコーポレイテッド 二官能性タンパク質およびその作製
EA202092417A1 (ru) 2018-04-10 2021-01-26 Амген Инк. Химерные рецепторы к dll3 и способы их применения
JP2021529516A (ja) 2018-06-18 2021-11-04 アンウィタ バイオサイエンシス， インク． サイトカイン融合タンパク質及びその使用
EP3856229A1 (en) 2018-09-28 2021-08-04 Pierre Fabre Medicament New immunocytokines for the treatment of cancer
KR20210107058A (ko) 2018-12-21 2021-08-31 오제 이뮈노테라프틱스 인간 pd-1에 대항하는 이작용성 분자

Also Published As

Publication number Publication date
JP2019122373A (ja) 2019-07-25
MX2020007291A (es) 2020-09-10
AU2019207895A1 (en) 2020-06-18
TW201930344A (zh) 2019-08-01
CR20200330A (es) 2020-12-23
PE20211270A1 (es) 2021-07-19
MA51631A (fr) 2020-11-18
JOP20200172A1 (ar) 2020-07-12
BR112020014121A2 (pt) 2020-12-01
CL2020001820A1 (es) 2020-10-02
CA3087273A1 (en) 2019-07-18
KR20200110358A (ko) 2020-09-23
CN111727197A (zh) 2020-09-29
EP3737694A1 (en) 2020-11-18
EP3737694B1 (en) 2023-03-01
ZA202004735B (en) 2023-06-28
IL275096A (en) 2020-07-30
US20190270817A1 (en) 2019-09-05
CR20210319A (es) 2021-07-27
US11518808B2 (en) 2022-12-06
ES2941740T3 (es) 2023-05-25
TN2020000142A1 (en) 2022-04-04
SG11202005605SA (en) 2020-07-29
CO2020009234A2 (es) 2020-10-30
PH12020550967A1 (en) 2021-03-22
WO2019140196A1 (en) 2019-07-18

Similar Documents

Publication Publication Date Title
UY38049A (es) Anti-pd-1 anticuerpos y métodos de tratamiento
BR112019003129A2 (pt) composição compreendendo um domínio de ligação a antígeno que se liga a tigit humano, composição de ácido nucleico e de vetor de expressão, célula hospedeira, e, métodos para preparação de um anticorpo anti-tigit e para tratar cancer.
CO2017008462A2 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
CY1125429T1 (el) Μουτεϊνες ιντερλευκινης-21 και μεθοδοι θεραπευτικης αγωγης
MX2022015823A (es) Receptores de antigenos quimerlcos basados en anticuerpos de dominio simple y metodos de uso de estos.
BR112018000696A2 (pt) ?anticorpo, métodos para reduzir e para aumentar a afinidade de ligação de um anticorpo que se liga ao cd3 humano, para tratar e para diagnosticar uma doença, para produzir um anticorpo e para detectar a presença de antígeno de cd3, construto de ácido nucleico, vetor de expressão, célula hospedeira, composição, e, kit?
BR112019011186A2 (pt) conjugado de anticorpo radiomarcado, composto, e, métodos de imageamento e para tratamento de um tumor.
EP4257199A3 (en) Humanized anti-human-pd-1 antibody
BR112018010385A2 (pt) anticorpo, receptor de antígeno quimérico, ácido nucleico, célula recombinante, processo para produção de um anticorpo ou um receptor de antígeno quimérico, composição, e, método para detecção de uma célula que expressa cll-1, para diagnóstico de uma doença, para inibição de divisão da célula e para tratamento de um câncer.
ZA202205383B (en) Novel anti-nogo-a antibodies
EA201992348A1 (ru) АНТИГЕН-СВЯЗЫВАЮЩИЕ БЕЛКИ, ВЗАИМОДЕЙСТВУЮЩИЕ С Jagged1
AR114079A1 (es) Anti-pd-1 anticuerpos y métodos de tratamiento
EA202091596A1 (ru) Антитела к pd-1 и способы лечения
AR111396A1 (es) Moléculas de unión antígeno biespecíficas capaces de unir específicamente a cd40 y a la proteína de activación de fibroblasto (fap)
EA201992136A1 (ru) Антитела против pd-l1

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20240513